Kangti Life completed tens of millions of yuan in Series A+ financing.

36Kr learned that "Kangti Life" announced today that it has completed a Series A+ financing round. As of now, the total financing amount has reached 70 million RMB, jointly invested by Jinyu Maowu, Livzon Pharmaceutical Group, Galaxy Capital, and Nanling Fund. The funds will be used to further expand the company's technology platform and market layout in nanobody discovery and modification services.